MedTrace Logo

Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab

NCT04964700 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2022-03-24

No results posted yet for this study

Summary

The purpose of this study is to explore the safety and efficacy data in clinic patients who have been treated with Natalizumab for more than 60 continuous infusions.

Conditions

Interventions

DRUG

Natalizumab

Monthly Infusions

Sponsors & Collaborators

  • Multiple Sclerosis Center of Northeastern New York

    lead OTHER

Principal Investigators

  • Keith R Edwards, M.D. · MS Center of Northeastern New York, P.C.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-06
Primary Completion
2022-04-01
Completion
2022-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04964700 on ClinicalTrials.gov